ORIC Pharmaceuticals (ORIC) Stock News
$ORIC · NASDAQ · 2 stories in 30 daysBORSA has published 2 stories on ORIC Pharmaceuticals (ORIC) in the past 30 days. BORSA’s news read on ORIC is bullish at 59/100, unchanged over 24 hours, based on 2 company events over the past 30 days. ORIC last closed at $11.81 on Oct 12, down 5.44% over five sessions and down 1.91% over the past month. ORIC Pharmaceuticals’ next earnings report is scheduled for Thursday, Nov 12.
The wire on $ORIC
newest first · updated · direct subject stories onlyORIC and Cancer Research UK to advance first-in-class CIP2A degrader ORIC-259
ORIC Pharmaceuticals partnered with Cancer Research UK to fully fund and execute early clinical development of ORIC-259, a first-in-class CIP2A mRNA degrader. ORIC retains an option to reacquire rights after Phase 1/2 data.
bullish 70 · impact 60